Acquisition Backdrop TearScience was acquired by Bausch Health in March 2023, signaling a potential channel shift, integration of ophthalmic portfolios, and access to larger distribution networks that can be leveraged for expanded sales of LipiFlow and related MGD technologies.

Meibomian Gland Demand MGD affects a large patient population and is a core focus of LipiFlow and LipiScan technologies, presenting a sizable market with opportunities to upsell to clinics seeking comprehensive eye surface disease solutions and repeatable meibomian gland assessment.

Clinical Evidence Extensive multicenter clinical studies demonstrate LipiFlow safety and sustained effectiveness, providing a credible foundation for sales conversations with high-volume ophthalmology practices and hospital systems aiming to standardize MGD treatment.

Global Reach & Partners Former Johnson & Johnson Vision lineage and subsequent acquisitions imply established relationships with ophthalmic distributors and possible cross-sell opportunities within broader eye-care portfolios and regional markets.

Growth levers Recent product introductions LipiScan and LipiFlow imaging, plus new treatment disposables, create upsell paths for clinics upgrading diagnostic capabilities and expanding therapy adoption, supported by a scalable tech stack and marketing automation.